Published: March 11, 2008
Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
BOSTON, March 11 /PRNewswire/ -- Replikins, Ltd. has announced development
of a chemically synthesized vaccine specific to a Taura Syndrome virus
structure based on its patented Replikins(TM) technology. When the vaccine was
administered orally to shrimp, 91% survived a challenge by the lethal Taura
virus. The specificity of the protective effect was established in control
groups by chemically blocking the active regions in the vaccine, and as a
result the protective effect was lost in these control groups. The
effectiveness of this vaccine, and its rapid production cycle (7 days),
represent an important proof of concept for developing vaccines against a
range of rapidly replicating high lethality virus outbreaks.
For counteracting emerging infectious disease, early detection and rapid
response are critical. Replikin contributions to date are both in early
detection and rapid response: 1) Advance warning previously was not possible
until it was found in H5N1 influenza that an increase in the virus replikin
concentration signalled one year in advance that the outbreak was coming, and
indicated the country in which this would occur (FluForecast(TM),Indonesia).
2) The production of vaccines by other methods has required 3 to 12 months, by
which time the epidemic may have come and gone, or the vaccine effectiveness
reduced or lost because the target changed due to mutation. In contrast, the
replikins vaccine found effective here was manufactured synthetically in 7
days.
Viruses lethal to shrimp have been responsible for large losses to
aquaculture worldwide. Replikins is forming a division to focus on these
viruses. The company is also pursuing development of synthetic vaccine
products based on replikin epitopes, Syntopes(TM), for the control of fish
hemorrhagic viruses and other lethal aquatic microorganisms,
Contact: Replikins Ltd., 38 The Fenway,Boston MA 02215.
email: sbogoch@replikins.com Tel: 646-320-5910
http://www.Replikins.com
This release was issued through eReleases(TM). For more information,
visit http://www.ereleases.com.
SOURCE Replikins Ltd.
Copyright © 2010, PRNewswire
Copyright © 2010, NewsBlaze,
Daily News
Tags: ,MTC,BIO,HEA,AGR,MA-Replikins-vaccine